相关实验视频

Updated: Jun 19, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

评估Hispidin对前列腺癌细胞的治疗效果

Kai-Cheng Chan¹, Praveenkumar Basavaraj¹, Jui-Chen Tsai²

¹Graduate Institute of Cell Biology, College of Life Sciences, China Medical University, Taichung 40402, Taiwan.

International journal of molecular sciences

|July 27, 2024

概括

希斯皮丁 (HPD) 是一种天然化合物,有效地抑制前列腺癌 (PCa) 细胞生长,迁移和入侵. 这项研究证实了HPD的存在.

科学领域:

自然产品化学自然产品化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

雄激素剥夺疗法 (ADT) 是晚期前列腺癌 (PCa) 的标准,但耐药性 (CRPC) 需要新的治疗方法.
希斯皮丁 (HPD) 是一种天然的多基化物,表现出多样化的生物活性,但缺乏PCa.的研究.
迫切需要新的治疗药物来克服PCa进展和ADT耐药性.

研究的目的:

评估Hispidin (HPD) 对雄激素敏感细胞和割抵抗性前列腺癌 (CRPC) 细胞的抗癌作用.
阐明HPD抗前列腺癌活性背后的分子机制.
评估HPD作为PCa的新型治疗剂的潜力.

主要方法:

细胞活力,迁移和入侵测定 (MTS,伤口愈合,穿孔).
西部斑点分析以评估蛋白质表达 (AR,MMP-2,MMP-9).
通过Annexin V-FITC/PI染色和Western blot (caspase通路) 来评估亡.

主要成果:

在体外,HPD抑制了PCa细胞生长,细胞循环进展,迁移和入侵.
HPD治疗降低了雄激素受体 (AR),MMP-2和MMP-9蛋白质的表达.
通过激活与卡斯巴酶相关的途径,HPD诱导了PCa细胞的亡.

结论:

希斯皮丁对前列腺癌细胞具有显著的抗癌特性.
HPD显示出作为一种新型治疗剂的潜力,可以延迟PCa的进展.
这项研究提供了对HPD抗PCa效应的机制性见解,支持其发展.

关键词:

在MMP中,MMP是MMP.治疗前列腺癌的治疗方法.灭症 (apoptosis) 是一种死亡的过程.他的皮丁是他的皮丁.自然化合物自然化合物

更多相关视频

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...